Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2003-06-13
2008-09-16
Campell, Bruce R. (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S389100, C424S159100
Reexamination Certificate
active
07425618
ABSTRACT:
The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.
REFERENCES:
patent: 4360457 (1982-11-01), Ono et al.
patent: 4374763 (1983-02-01), Takagi
patent: 4526938 (1985-07-01), Churchill et al.
patent: 4597966 (1986-07-01), Zolton et al.
patent: 4703039 (1987-10-01), Hawiger et al.
patent: 4800078 (1989-01-01), Prince et al.
patent: 4880078 (1989-11-01), Inoue et al.
patent: 4992419 (1991-02-01), Woog et al.
patent: 5128326 (1992-07-01), Balazs et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5290540 (1994-03-01), Prince et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5608038 (1997-03-01), Eibl et al.
patent: 5679377 (1997-10-01), Bernstein et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5739277 (1998-04-01), Presta et al.
patent: 5747035 (1998-05-01), Presta et al.
patent: 5762905 (1998-06-01), Burton et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5840298 (1998-11-01), Brams et al.
patent: 5855913 (1999-01-01), Hanes et al.
patent: 5866125 (1999-02-01), Brams et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5871736 (1999-02-01), Bruegger et al.
patent: 5874064 (1999-02-01), Edwards et al.
patent: 5912015 (1999-06-01), Bernstein et al.
patent: 5916597 (1999-06-01), Lee et al.
patent: 5934272 (1999-08-01), Lloyd et al.
patent: 5939068 (1999-08-01), Brams et al.
patent: 5955364 (1999-09-01), Brams et al.
patent: 5958765 (1999-09-01), Brams et al.
patent: 5961927 (1999-10-01), Isaacs et al.
patent: 5985309 (1999-11-01), Edwards et al.
patent: 5985320 (1999-11-01), Edwards et al.
patent: 5989463 (1999-11-01), Tracy et al.
patent: 6019968 (2000-02-01), Platz et al.
patent: 6096551 (2000-08-01), Barbas et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6277375 (2001-08-01), Ward
patent: 6537809 (2003-03-01), Brams et al.
patent: 6565849 (2003-05-01), Koenig
patent: 6572856 (2003-06-01), Taylor et al.
patent: 6586008 (2003-07-01), Batycky et al.
patent: 6656467 (2003-12-01), Young et al.
patent: 6685942 (2004-02-01), Burton et al.
patent: 6818216 (2004-11-01), Young et al.
patent: 6855493 (2005-02-01), Young et al.
patent: 7132100 (2006-11-01), Oliver et al.
patent: 2001/0034062 (2001-10-01), Koenig
patent: 2002/0004046 (2002-01-01), Johnson
patent: 2002/0018780 (2002-02-01), Koenig et al.
patent: 2002/0051787 (2002-05-01), Prince et al.
patent: 2002/0098189 (2002-07-01), Young et al.
patent: 2002/0102257 (2002-08-01), Johnson
patent: 2002/0177126 (2002-11-01), Young et al.
patent: 2003/0190311 (2003-10-01), Johnson et al.
patent: 2004/0005324 (2004-01-01), Pilkington et al.
patent: 2004/0018200 (2004-01-01), Oliver et al.
patent: 2004/0018243 (2004-01-01), Basu et al.
patent: 2004/0202721 (2004-10-01), Lipp et al.
patent: 2005/0147616 (2005-07-01), Young et al.
patent: 2006/0034827 (2006-02-01), Oliver et al.
patent: 0 025 321 (1981-03-01), None
patent: 0 025 719 (1981-03-01), None
patent: 0 368 684 (1990-05-01), None
patent: 0 420 649 (1990-09-01), None
patent: 0 413 622 (1991-02-01), None
patent: 0 327 378 (1996-12-01), None
patent: 1 314 437 (2003-05-01), None
patent: 2758331 (1998-07-01), None
patent: 1268646 (1989-10-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 91/04743 (1991-04-01), None
patent: WO 91/05548 (1991-05-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 92/19244 (1992-11-01), None
patent: WO 93/15199 (1993-08-01), None
patent: WO 93/15200 (1993-08-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/06448 (1994-03-01), None
patent: WO 96/05229 (1996-02-01), None
patent: WO 96/20698 (1996-07-01), None
patent: WO 96/32478 (1996-10-01), None
patent: WO 97/32572 (1997-09-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/43316 (1997-11-01), None
patent: WO 97/44013 (1997-11-01), None
patent: WO 97/45140 (1997-12-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/31346 (1998-07-01), None
patent: WO 98/56418 (1998-12-01), None
patent: WO 99/15154 (1999-04-01), None
patent: WO 99/20253 (1999-04-01), None
patent: WO 99/43783 (1999-09-01), None
patent: WO 99/66903 (1999-12-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/10541 (2000-03-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 01/55217 (2001-08-01), None
patent: WO 01/64751 (2001-09-01), None
patent: WO 01/77137 (2001-10-01), None
patent: WO 02/060919 (2001-12-01), None
patent: WO 02/13860 (2002-02-01), None
Meissner et al., Safety and Pharmacokinetics of an Intramuscular Monoclonal Antibody (SB 209763) against Respiratory Syncytial Virus (RSV) in Infants and Young Children at Risk for Severe RSV DiseaseAntimicrob. Agents Chemother. 1999 43:1183-1188.
U.S. Appl. No. 60/388,921, filed Jun. 14, 2002, Oliver et al.
U.S. Appl. No. 10/403,180, filed Mar. 31, 2003, Young et al.
U.S. Appl. No. 09/724,531, filed Nov. 28, 2000, Young et al.
U.S. Appl. No. 09/724,396, filed Nov. 28, 2000, Young et al.
Abman et al., 1988, “Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis,” J. Pediatr. 113(5):826-830.
Ahouse et al., 1993, “Mouse MHC class I-like Fc receptor encoded outside the MHC,”J. Immunol.151(11):6076-6088.
American Academy of Pediatrics, 2000, “Summaries of Infectious Diseases,” in: 2000Red Book: Report of the Committee on Infectious Diseases, 25thed., Pickering, ed., Elk Grove Village, IL pp. 483-487.
American Academy of Pediatrics Committee on Infectious Diseases, 1993, “Use of ribavirin in the treatment of respiratory syncytial virus infection,” Pediatrics 92(3):501-504.
Anderson et al., 1985, “Microneutralization test for respiratory syncytial virus based on an enzyme immunoassay,” J. Clin. Microbiol. 22:1050-1052.
Beeler et al., 1989, “Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function,” J. Virol. 63(7):2941-2950.
Bentley et al., 1980, “Human immunoglobulin variable region genes—DNA sequences of two V kappa genes and a pseudogene,” Nature 288(5792):730-733.
Borvak et al., 1998, “Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice,” Int. Immunol. 10(9):1289-1298.
Botts et al., 1984, “On the mechanism of energy transduction in myosin subfragment I,” Proc. Natl. Acad. Sci. USA 81(7):2060-2064.
Boulianne et al., 1984, “Production of functional chimaeric mouse/human antibody,” Nature 312(5995):643-646.
Burmeister et al., 1994, “Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor,” Nature 372(6504):336-343.
Burmeister et al., 1994, “Crystal structure of the complex of rat neonatal Fc receptor with Fc,” Nature 372(6504):379-383.
Byrd et al., 1997, “Animal models of respiratory syncytial virus infection,” Clin. Infect. Dis. 25(6):1363-1368.
Carson et al., 1986, “Human lymphocyte hybridomas and monoclonal antibodies,” Adv. Immunol. 38:275-311.
Chintalacharuvu et al., 2001, “Hybrid IgA2/IgG1 antibodies with tailor-made effector functions,” Clin. Immun
Allan Christian B.
Chang Stephen T.
Oliver Cynthia N.
Campell Bruce R.
Hill Myron G.
Jones Day
Medimmune Inc.
LandOfFree
Stabilized anti-respiratory syncytial virus (RSV) antibody... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stabilized anti-respiratory syncytial virus (RSV) antibody..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stabilized anti-respiratory syncytial virus (RSV) antibody... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3988300